Copyright
©The Author(s) 2023.
World J Hepatol. Feb 27, 2023; 15(2): 237-254
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.237
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.237
Table 5 Comparison of antiviral data of chronic hepatitis B virus infection with and without nonalcoholic fatty liver disease, n (%)
| Parameters | NAFLD | No NAFLD | P value |
| (n = 152) | (n = 304) | ||
| Antiviral | 116 (76.3) | 215 (70.7) | 0.21 |
| Antiviral drugs | 0.5 | ||
| Entecavir | 73 (62.9) | 131 (60.9) | |
| Tenofovir | 35 (30.2) | 68 (31.6) | |
| Others | 8 (6.9) | 16 (7.4) | |
| Antivirus duration | 0.31 | ||
| < 5 yr | 70 (46.1) | 129 (42.4) | |
| ≥ 5 yr | 46 (30.3) | 86 (28.3) |
- Citation: Tan YW, Wang JM, Zhou XB. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. World J Hepatol 2023; 15(2): 237-254
- URL: https://www.wjgnet.com/1948-5182/full/v15/i2/237.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i2.237